Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we ...

Global Blood Therapeutics has seen its sickle cell disease drug approved by the FDA, promising to be the first treatment targeting the root cause of the condition.

His previous roles include Chief Research and Development Officer at Reata Pharmaceuticals (NASDAQ:RETA), as well as executive positions at Global Blood Therapeutics (NASDAQ:GBT), Portola ...

Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...

This groundbreaking therapy—benchmarked to global standards ... increasing incidence of blood cancer cases, Qartemi—a pioneering CAR-T cell therapy from Immuneel Therapeutics—stands ...

Earlier, Dr. Patni was Chief Medical Officer at Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals, until their acquisitions by larger companies. He also held roles of ...